Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors.
Gregorc V, De Braud FG, De Pas TM, Scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Cappio F, Lambiase A, Bordignon C. Gregorc V, et al. Clin Cancer Res. 2011 Apr 1;17(7):1964-72. doi: 10.1158/1078-0432.CCR-10-1376. Epub 2011 Feb 9. Clin Cancer Res. 2011. PMID: 21307147 Clinical Trial.
KRAS in NSCLC: State of the Art and Future Perspectives.
Cascetta P, Marinello A, Lazzari C, Gregorc V, Planchard D, Bianco R, Normanno N, Morabito A. Cascetta P, et al. Among authors: gregorc v. Cancers (Basel). 2022 Nov 4;14(21):5430. doi: 10.3390/cancers14215430. Cancers (Basel). 2022. PMID: 36358848 Free PMC article. Review.
Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.
Cappuzzo F, Selvaggi G, Gregorc V, Mazzoni F, Betti M, Rita Migliorino M, Novello S, Maestri A, De Marinis F, Darwish S, De Angelis V, Nelli F, Bartolini S, Scagliotti GV, Tonato M, Crinò L. Cappuzzo F, et al. Among authors: gregorc v. Cancer. 2003 Jul 1;98(1):128-34. doi: 10.1002/cncr.11460. Cancer. 2003. PMID: 12833465 Free article. Clinical Trial.
Endothelial growth factor receptor inhibition after radiotherapy.
Giovannini M, Gregorc V, Viganò MG, Spreafico A, Ghio D, Dell'Oca I, Bolognesi A, Villa E. Giovannini M, et al. Among authors: gregorc v. J Thorac Oncol. 2007 Jul;2(7):662. doi: 10.1097/JTO.0b013e318074de48. J Thorac Oncol. 2007. PMID: 17607125 Free article. No abstract available.
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours.
Gregorc V, Santoro A, Bennicelli E, Punt CJ, Citterio G, Timmer-Bonte JN, Caligaris Cappio F, Lambiase A, Bordignon C, van Herpen CM. Gregorc V, et al. Br J Cancer. 2009 Jul 21;101(2):219-24. doi: 10.1038/sj.bjc.6605162. Epub 2009 Jun 30. Br J Cancer. 2009. PMID: 19568235 Free PMC article. Clinical Trial.
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours.
Gregorc V, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti A, Caligaris-Cappio F, Del Maschio A, Esposito A, De Cobelli F, Dell'Acqua F, Troysi A, Bruzzi P, Lambiase A, Bordignon C. Gregorc V, et al. Eur J Cancer. 2010 Jan;46(1):198-206. doi: 10.1016/j.ejca.2009.10.005. Eur J Cancer. 2010. PMID: 19900802 Clinical Trial.
114 results